GAMMA Investing LLC lifted its holdings in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 32,941.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,858,887 shares of the financial services provider's stock after buying an additional 1,853,261 shares during the period. GAMMA Investing LLC owned about 0.52% of CME Group worth $493,144,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of CME Group by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 34,243,090 shares of the financial services provider's stock worth $7,952,273,000 after acquiring an additional 326,623 shares during the period. Geode Capital Management LLC grew its holdings in shares of CME Group by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 8,389,442 shares of the financial services provider's stock worth $1,946,717,000 after acquiring an additional 104,697 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of CME Group by 89.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after acquiring an additional 3,921,278 shares during the period. Norges Bank acquired a new stake in CME Group during the 4th quarter valued at $1,107,389,000. Finally, FIL Ltd grew its holdings in CME Group by 1.5% during the 4th quarter. FIL Ltd now owns 4,081,391 shares of the financial services provider's stock valued at $947,821,000 after buying an additional 61,908 shares during the last quarter. Institutional investors and hedge funds own 87.75% of the company's stock.
Insider Buying and Selling at CME Group
In other CME Group news, Director Charles P. Carey sold 3,000 shares of CME Group stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $272.56, for a total transaction of $817,680.00. Following the transaction, the director now directly owns 5,400 shares in the company, valued at approximately $1,471,824. The trade was a 35.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel G. Kaye sold 500 shares of CME Group stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total transaction of $141,210.00. Following the transaction, the director now owns 3,668 shares in the company, valued at approximately $1,035,916.56. The trade was a 12.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,900 shares of company stock valued at $6,147,935. Corporate insiders own 0.30% of the company's stock.
CME Group Price Performance
NASDAQ:CME traded down $8.40 during midday trading on Tuesday, hitting $282.31. 2,723,627 shares of the stock were exchanged, compared to its average volume of 2,188,928. CME Group Inc. has a one year low of $190.70 and a one year high of $290.79. The company has a market capitalization of $101.73 billion, a price-to-earnings ratio of 29.19, a P/E/G ratio of 6.76 and a beta of 0.45. The business has a 50-day moving average price of $270.54 and a two-hundred day moving average price of $251.90. The company has a current ratio of 1.01, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10.
CME Group (NASDAQ:CME - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.61 by $0.19. The firm had revenue of $1.64 billion for the quarter, compared to analysts' expectations of $1.56 billion. CME Group had a return on equity of 13.62% and a net margin of 57.52%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.50 earnings per share. Sell-side analysts predict that CME Group Inc. will post 10.49 EPS for the current year.
CME Group Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th will be issued a $1.25 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $5.00 annualized dividend and a dividend yield of 1.77%. CME Group's dividend payout ratio is currently 50.30%.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. Raymond James upgraded CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 target price on the stock in a report on Monday, March 10th. Royal Bank of Canada restated a "sector perform" rating and set a $269.00 price objective on shares of CME Group in a report on Thursday, April 3rd. Barclays raised their price objective on CME Group from $279.00 to $283.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 23rd. Morgan Stanley increased their target price on CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Finally, Keefe, Bruyette & Woods increased their target price on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $256.80.
View Our Latest Research Report on CME Group
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Recommended Stories
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
